Skip to main content

Animations

MJFF Publications

7971 - 7980 of 8801 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2019
  • 2019
  • Summary Details
    RESTRICTED
    Title: Pompe disease treated before birth
    Journal Name: Nature Biotechnology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1038/s41587-022-01621-7
    Citation Count: 2
  • Summary Details
    RESTRICTED
    Title: Parkinson’s disease drug hunters think outside the α-synuclein box
    Journal Name: Nature Biotechnology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1038/s41587-022-01610-w
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables
    Journal Name: Neurological Sciences
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s10072-022-06061-4
    Citation Count: 21
  • Summary Details
    OPEN
    Title: Screening performances of an 8-item UPSIT Italian version in the diagnosis of Parkinson’s disease
    Journal Name: Neurological Sciences
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s10072-022-06457-2
    Citation Count: 6
  • Summary Details
    OPEN
    Title: A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s13311-022-01199-7
    Citation Count: 15
  • Summary Details
    OPEN
    Title: The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
    Journal Name: PharmacoEconomics
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s40273-022-01132-y
    Citation Count: 10
  • Summary Details
    OPEN
    Title: Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41598-022-07706-2
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Leveraging Patient Preference Information in Medical Device Clinical Trial Design
    Journal Name: Therapeutic Innovation & Regulatory Science
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s43441-022-00450-9
    Citation Count: 7
  • Summary Details
    OPEN
    Title: The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease
    Journal Name: Cell Death & Differentiation
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41418-019-0408-4
    Citation Count: 113
  • Summary Details
    OPEN
    Title: Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload
    Journal Name: Cell Death & Differentiation
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41418-019-0442-2
    Citation Count: 34
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.